These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 25471584)

  • 41. Hypothermia is not neuroprotective after infection-sensitized neonatal hypoxic-ischemic brain injury.
    Osredkar D; Thoresen M; Maes E; Flatebø T; Elstad M; Sabir H
    Resuscitation; 2014 Apr; 85(4):567-72. PubMed ID: 24361672
    [TBL] [Abstract][Full Text] [Related]  

  • 42. FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice.
    Nofer JR; Bot M; Brodde M; Taylor PJ; Salm P; Brinkmann V; van Berkel T; Assmann G; Biessen EA
    Circulation; 2007 Jan; 115(4):501-8. PubMed ID: 17242282
    [TBL] [Abstract][Full Text] [Related]  

  • 43. FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors.
    Chiba K
    Pharmacol Ther; 2005 Dec; 108(3):308-19. PubMed ID: 15951022
    [TBL] [Abstract][Full Text] [Related]  

  • 44. FTY720 ameliorates Th1-mediated colitis in mice by directly affecting the functional activity of CD4+CD25+ regulatory T cells.
    Daniel C; Sartory N; Zahn N; Geisslinger G; Radeke HH; Stein JM
    J Immunol; 2007 Feb; 178(4):2458-68. PubMed ID: 17277153
    [TBL] [Abstract][Full Text] [Related]  

  • 45. FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory.
    Pinschewer DD; Ochsenbein AF; Odermatt B; Brinkmann V; Hengartner H; Zinkernagel RM
    J Immunol; 2000 Jun; 164(11):5761-70. PubMed ID: 10820254
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Combined in utero hypoxia-ischemia and lipopolysaccharide administration in rats induces chorioamnionitis and a fetal inflammatory response syndrome.
    Maxwell JR; Denson JL; Joste NE; Robinson S; Jantzie LL
    Placenta; 2015 Dec; 36(12):1378-84. PubMed ID: 26601766
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720.
    Zemann B; Kinzel B; Müller M; Reuschel R; Mechtcheriakova D; Urtz N; Bornancin F; Baumruker T; Billich A
    Blood; 2006 Feb; 107(4):1454-8. PubMed ID: 16223773
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evidence that FTY720 induces T cell apoptosis in vivo.
    Nagahara Y; Enosawa S; Ikekita M; Suzuki S; Shinomiya T
    Immunopharmacology; 2000 Jun; 48(1):75-85. PubMed ID: 10822091
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis.
    Mehling M; Johnson TA; Antel J; Kappos L; Bar-Or A
    Neurology; 2011 Feb; 76(8 Suppl 3):S20-7. PubMed ID: 21339487
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Recent trials for FTY720 (fingolimod): a new generation of immunomodulators structurally similar to sphingosine.
    Mansoor M; Melendez AJ
    Rev Recent Clin Trials; 2008 Jan; 3(1):62-9. PubMed ID: 18474015
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cutting edge: Alternative signaling of Th17 cell development by sphingosine 1-phosphate.
    Liao JJ; Huang MC; Goetzl EJ
    J Immunol; 2007 May; 178(9):5425-8. PubMed ID: 17442922
    [TBL] [Abstract][Full Text] [Related]  

  • 52. FTY720 preferentially depletes naive T cells from peripheral and lymphoid organs.
    Hofmann M; Brinkmann V; Zerwes HG
    Int Immunopharmacol; 2006 Dec; 6(13-14):1902-10. PubMed ID: 17161343
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The neurobiology of sphingosine 1-phosphate signaling and sphingosine 1-phosphate receptor modulators.
    Soliven B; Miron V; Chun J
    Neurology; 2011 Feb; 76(8 Suppl 3):S9-14. PubMed ID: 21339490
    [TBL] [Abstract][Full Text] [Related]  

  • 54. FTY720: altered lymphocyte traffic results in allograft protection.
    Brinkmann V; Pinschewer DD; Feng L; Chen S
    Transplantation; 2001 Sep; 72(5):764-9. PubMed ID: 11571432
    [No Abstract]   [Full Text] [Related]  

  • 55. FTY720 pretreatment reduces warm hepatic ischemia reperfusion injury through inhibition of T-lymphocyte infiltration.
    Anselmo DM; Amersi FF; Shen XD; Gao F; Katori M; Lassman C; Ke B; Coito AJ; Ma J; Brinkmann V; Busuttil RW; Kupiec-Weglinski JW; Farmer DG
    Am J Transplant; 2002 Oct; 2(9):843-9. PubMed ID: 12392290
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Basic mechanisms of action of fingolimod in relation to multiple sclerosis].
    García-Merino JA; Sánchez AJ
    Rev Neurol; 2012 Jul; 55(1):31-7. PubMed ID: 22718407
    [TBL] [Abstract][Full Text] [Related]  

  • 57. FTY720 impairs CD8 T-cell function independently of the sphingosine-1-phosphate pathway.
    Ntranos A; Hall O; Robinson DP; Grishkan IV; Schott JT; Tosi DM; Klein SL; Calabresi PA; Gocke AR
    J Neuroimmunol; 2014 May; 270(1-2):13-21. PubMed ID: 24680062
    [TBL] [Abstract][Full Text] [Related]  

  • 58. FTY720 attenuates accumulation of EMAP-II+ and MHC-II+ monocytes in early lesions of rat traumatic brain injury.
    Zhang Z; Zhang Z; Fauser U; Artelt M; Burnet M; Schluesener HJ
    J Cell Mol Med; 2007; 11(2):307-14. PubMed ID: 17488479
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Fingolimod phosphate promotes the neuroprotective effects of microglia.
    Noda H; Takeuchi H; Mizuno T; Suzumura A
    J Neuroimmunol; 2013 Mar; 256(1-2):13-8. PubMed ID: 23290828
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Selective lymphocyte inhibition by FTY720 slows the progressive course of chronic anti-thy 1 glomerulosclerosis.
    Peters H; Martini S; Wang Y; Shimizu F; Kawachi H; Krämer S; Neumayer HH
    Kidney Int; 2004 Oct; 66(4):1434-43. PubMed ID: 15458436
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.